https://www.selleckchem.com/products/AZD0530.html With our registration software and imaging processing algorithms, we were able to correlate individual druse sizes measured on CFP with those determined on SD-OCT. These data can be used to develop an SD-OCT-based grading scale, analogous to the CFP AREDS drusen scale, that may be useful in the clinic and in clinical trials. With our registration software and imaging processing algorithms, we were able to correlate individual druse sizes measured on CFP with those determined on SD-OCT. These data can be used to develop an SD-OCT-based grading scale, analogous to the CFP AREDS drusen scale, that may be useful in the clinic and in clinical trials. To evaluate 18 months' results of a strict anti-VEGF protocol for radiation maculopathy (RM) following proton therapy in choroidal melanoma. Retrospective, comparative, non-randomized study of 74 RM patients presenting macular lipid deposits, hemorrhages, microaneurysms, cystoid edema, nerve layer infarction, telangiectasia or capillary nonperfusion. The study group included 52 consecutive patients injected with intravitreal anti-VEGFs (bevacizumab/ranibizumab 46/6) every two months for the first and every three months for the second year, with minimum 12 months' follow-up. The control group consisted of 22 patients having declined this treatment. BCVA, SD-OCT and OCTA were recorded at baseline, 6, 12 and 18 months. The foveal avascular zone (FAZ) and capillary density (CD) were measured at the superficial capillary plexus. RM was diagnosed at 2 years [1.5-3.5] after proton therapy. BCVA at baseline, 12 and 18 months improved in the study group from 0.45, 0.3 to 0.2 LogMar, but decreased in the control group from 0.5, 0.9 to 1.0 LogMar respectively (p<0.001 at 12 months). Simultaneously, FAZ enlargement was less in the study (from 0.377, 0.665 to 0.744 mm2) than control group (from 0.436, 1.463 to 2.638 mm2) (p=0.05 at 12 months). CMT (280 and 276 µm) and CD (37 and 38%, at b